Akari's Coversin meets in Phase II for PNH

Akari Therapeutics plc (NASDAQ:AKTX) said subcutaneous Coversin met the primary endpoint of reducing lactic dehydrogenase (LDH) to ≤1.8 times the upper limit of normal (ULN) at day 28 in the open-label Phase II COBALT trial in eight patients with paroxysmal nocturnal hemoglobinuria (PNH) who have never received a complement blocking therapy. No treatment-related serious adverse events were reported.

Secondary endpoints in the trial include hemoglobin, haptoglobin, Functional Assessment of Chronic Illness Therapy (FACIT) score, Quality of Life Questionnaire (QOQ) score and safety...